Government award will advance the company's non-vaccine influenza therapeutic, CD388, and onshore its manufacturing ahead of a potential pandemic.
The communications technology firm has completed its merger with Core Gaming and will relaunch on October 7th as an artificial intelligence holding company.
Regulators expedite review for ALTO-101, targeting a key aspect of schizophrenia with no currently approved treatments.
The sale of the controlling interest in the insurance platform represents a significant and rapid return on investment for White Mountains.
With a potential market of 128 million in the U.S., analysts see blockbuster potential for the new presbyopia treatment.
Positive Phase 1 results for the company's epilepsy drug candidate are coupled with a significant financing deal that could dilute shares.
Tecentriq in combination with Zepzelca approved as a first-line maintenance treatment for extensive-stage small cell lung cancer, a significant advancement for a hard-to-treat cancer.
Disruption at a key California facility could tighten fuel markets, boosting margins for competing refiners in an already vulnerable region.